Also trades as: 092730.KS (KSC) · $vol 0M
092730.KQ KOE
NeoPharm Co. Ltd.
1W: -2.3%
1M: -4.9%
3M: +24.9%
YTD: +15.6%
1Y: +22.7%
3Y: +11.4%
5Y: -22.8%
₩23,100.00 ($17.17)
-200.00 (-0.86%)
Weekly Expected Move ±5.0%
₩20781
₩21940
₩23100
₩24260
₩25419
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$220.3B
+14.5% ▲
5Y CAGR: +10.6%
Total Liabilities
$24.9B
+60.2% ▲
5Y CAGR: +10.3%
Shareholders Equity
$195.4B
+10.4% ▲
5Y CAGR: +10.7%
Cash & Investments
$141.7B
+12.0% ▲
5Y CAGR: +8.1%
Total Debt
$1.9B
+204.3% ▲
5Y CAGR: -14.9%
Net Debt
-$24.9B
-41.5% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $7.0B | $10.9B | $11.9B | $18.2B | $26.8B |
| Short-Term Investments | $98.0B | $102.6B | $100.1B | $108.3B | $114.9B |
| Cash & ST Investments | $105.0B | $113.5B | $112.0B | $126.5B | $141.7B |
| Net Receivables | $8.0B | $7.7B | $8.6B | $12.8B | $14.4B |
| Inventory | $8.0B | $8.7B | $10.2B | $12.7B | $15.6B |
| Other Current Assets | $0 | $1.1B | $3.0B | $565M | $913M |
| Total Current Assets | $121.5B | $131.3B | $134.5B | $153.0B | $176.5B |
| Property, Plant & Equip. | $9.7B | $9.3B | $29.2B | $29.8B | $30.2B |
| Goodwill & Intangibles | $2.1B | $1.8B | $2.2B | $2.0B | $1.8B |
| Long-Term Investments | $9.3B | $12.2B | $10.5B | -$106.4B | $7.4B |
| Other Non-Current Assets | $646M | $638M | $1.0B | $114.0B | $1.6B |
| Total Non-Current Assets | $21.9B | $24.1B | $43.0B | $39.4B | $43.8B |
| Total Assets | $143.4B | $155.3B | $177.5B | $192.4B | $220.3B |
| — Liabilities — | |||||
| Accounts Payable | $4.3B | $3.7B | $6.4B | $5.0B | $7.7B |
| Short-Term Debt | $19M | $19M | $18M | $500M | $1.1B |
| Deferred Revenue | $585M | $567M | $0 | $0 | $740M |
| Other Current Liabilities | $7.6B | $8.5B | $9.9B | $783M | $7.5B |
| Total Current Liabilities | $12.9B | $13.1B | $16.9B | $15.1B | $21.0B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $61M | $0 | $58M | $299M | $429M |
| Total Non-Current Liabilities | $162M | $0 | $488M | $428M | $3.9B |
| Total Liabilities | $13.1B | $13.1B | $17.4B | $15.6B | $24.9B |
| — Equity — | |||||
| Common Stock | $4.1B | $4.1B | $4.1B | $8.0B | $8.0B |
| Retained Earnings | $83.8B | $96.1B | $113.6B | $130.6B | $144.1B |
| Accumulated OCI | -$138M | -$490M | -$172M | -$243M | $5.3B |
| Total Stockholders Equity | $130.3B | $142.2B | $160.0B | $176.9B | $195.4B |
| Total Liabilities & Equity | $143.4B | $155.3B | $177.5B | $192.4B | $220.3B |
| — Key Metrics — | |||||
| Total Debt | $559M | $412M | $1.1B | $629M | $1.9B |
| Net Debt | -$6.5B | -$10.5B | -$10.8B | -$17.6B | -$24.9B |
| Total Investments | $107.3B | $114.8B | $110.6B | $1.9B | $122.3B |